The estimated Net Worth of Stephen Machatha is at least $1.64 Milión dollars as of 12 August 2024. Stephen Machatha owns over 16,041 units of Aldeyra Therapeutics Inc stock worth over $1,465,612 and over the last 4 years he sold ALDX stock worth over $174,566. In addition, he makes $0 as Senior Vice President a Technical Operations at Aldeyra Therapeutics Inc.
Sign up
Stephen Machatha ALDX stock SEC Form 4 insiders trading
Stephen has made over 2 trades of the Aldeyra Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 16,041 units of ALDX stock worth $76,034 on 12 August 2024.
The largest trade he's ever made was selling 29,768 units of Aldeyra Therapeutics Inc stock on 9 March 2024 worth over $98,532. On average, Stephen trades about 7,635 units every 26 days since 2021. As of 12 August 2024 he still owns at least 236,771 units of Aldeyra Therapeutics Inc stock.
You can see the complete history of Stephen Machatha stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Machatha biography
Dr. Stephen Machatha Ph. D. serves as Senior Vice President, Technical Operations of the Company. Dr. Machatha joined Aldeyra in 2016 as Vice President of Chemistry Manufacturing and Controls. Prior to joining Aldeyra, from January 2014 to December 2015, Dr. Machatha was Director of Chemistry Manufacturing and Controls and Drug Product Development for Synageva Biopharmaceuticals, a biotechnology company acquired by Alexion Pharmaceuticals. Dr. Machatha led the Chemistry Manufacturing and Controls teams involved in the development and regulatory filing of KANUMATM (sebelipase alfa). Prior to his work at Synageva, Dr. Machatha held scientific and product development roles of increasing responsibilities at Cubist Pharmaceuticals (Acquired by Merck & Co.) and CyDex Pharmaceuticals (Acquired by Ligand Pharmaceuticals). Dr. Machatha attended the University of Arizona, where he received a Ph.D. in Pharmaceutical Sciences, an M.A. in Chemistry, and a B.Sc. in Chemistry.
How old is Stephen Machatha?
Stephen Machatha is 43, he's been the Senior Vice President a Technical Operations of Aldeyra Therapeutics Inc since 2019. There are 14 older and no younger executives at Aldeyra Therapeutics Inc. The oldest executive at Aldeyra Therapeutics Inc is Jesse Treu, 73, who is the Independent Director.
What's Stephen Machatha's mailing address?
Stephen's mailing address filed with the SEC is C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON, MA, 02421.
Insiders trading at Aldeyra Therapeutics Inc
Over the last 11 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson... a Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.
What does Aldeyra Therapeutics Inc do?
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
What does Aldeyra Therapeutics Inc's logo look like?
Complete history of Stephen Machatha stock trades at Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc executives and stock owners
Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Todd Brady,
President, Chief Executive Officer, Director -
Joshua Reed,
Chief Financial Officer -
David McMullin,
Chief Commercial Officer -
Dr. Todd C. Brady M.D., Ph.D.,
CEO, Pres & Director -
Joshua Reed M.B.A.,
Chief Financial Officer -
Richard Douglas,
Independent Chairman of the Board -
Martin Joyce,
Independent Director -
Jesse Treu,
Independent Director -
Ben Bronstein,
Independent Director -
Gary Phillips,
Independent Director -
Neal Walker,
Independent Director -
Scott Solomon,
IR Contact Officer -
Nancy Miller-rich,
Independent Director -
Stephen Machatha,
Senior Vice President, Technical Operations -
James Gow,
Senior Vice President - Clinical Development -
Bruce Greenberg CPA, M.B.A.,
VP & Controller -
Dr. Stephen G. Machatha Ph.D.,
Chief Devel. Officer -
Kelly Mizer,
VP of Commercial Strategy & Operations -
David J Clark,
Chief Medical Officer -
Advisors Llcedelman Josephp...,
-
C. Boyd Clarke,
Director -
Stephen J Tulipano,
Chief Financial Officer -
Scott Young,
Chief Operating Officer -
Bruce Greenberg,
See Remarks -
Advisors Llcperceptive Life...,
-
Partners Vi, L.P.Blair Jame...,
-
& Johnson Johnson & Johnson...,
-
Vi Associates, L.P.Blair Ja...,